ARTICLE | Emerging Company Profile
Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline
Emerging Company Profile: Inipharm will use its $35M series A to advance lead liver program through Phase I
November 14, 2020 4:08 AM UTC
Inipharm debuted Wednesday with $35 million in series A funding, a team of Mavupharma veterans and a small molecule portfolio targeting an enzyme that is upregulated across a handful of liver diseases.
5AM Ventures and Wu Capital joined existing investors Frazier Healthcare Partners and Jubilant Biosys Ltd. to fund the round...